Why carry out this study?

The presence or absence of cirrhosis in patients with chronic hepatitis C virus (HCV) infection influences the type and duration of antiviral therapy.

Non-invasive markers, like serum aspartate aminotransferase (AST) to platelet ratio index (APRI), may help identify appropriate HCV treatment-naive patients for 8-week treatment with the pangenotypic regimen of glecaprevir/pibrentasvir in countries where 8-week G/P treatment in patients with compensated cirrhosis may take longer to get approved.

What was learned from the study?

Glecaprevir/pibrentasvir was highly efficacious and well tolerated in HCV treatment-naïve patients with APRI ≤ 1 and no prior evidence of cirrhosis.

Use of APRI may help HCV elimination efforts by simplifying care pathways and treatment scale-up in community-based settings with glecaprevir/pibrentasvir.